Patent ọhụrụ nke Japanese na ọgwụ mgbochi ọrịa cancer ovarian

Anixa Biosciences, Inc., ụlọ ọrụ biotechnology lekwasịrị anya na ọgwụgwọ na mgbochi nke ọrịa cancer na ọrịa na-efe efe, taa mara ọkwa na ụlọ ọrụ patent Japanese enyela mkpebi inye onyinye nke patent na Cleveland Clinic akpọrọ, "Vaccines Ovarian Cancer Vaccines." Ọ bụ Drs chepụtara teknụzụ a. Vincent K. Tuohy, Suparna Mazumder na Justin M. Johnson na Cleveland Clinic. Anixa bụ onye nyere ikike maka teknụzụ ọgwụ mgbochi n'ụwa niile. Enyere patent maka teknụzụ na US na Europe na 2021.  

Print Friendly, PDF & Email

"Obi dị anyị ụtọ ịkpọsa nchebe akụrụngwa ọgụgụ isi nke ọgwụ mgbochi ọrịa cancer ovarian nke Anixa, nke e mepụtara na Cleveland Clinic ma na-amụ na NCI. Nkà na ụzụ a pụrụ iche nwere ike ịbụ ọgwụ mgbochi mbụ iji gbochie ọrịa cancer ovarian, bụ nke na-anọgide na-abụ otu n'ime ọrịa cancer kachasị njọ na nke siri ike ịgwọ ọrịa," Dr. Amit Kumar, CEO, President na CEO nke Anixa Biosciences kwuru. "Ọ bụrụ na ọ na-aga nke ọma, ọgwụ mgbochi a nwere ike igbochi ọrịa cancer ovarian ka ọ ghara ịpụta mgbe ọ bụla ma mee ka ndị ọrịa ghara ịnara chemotherapy na ọgwụgwọ ịwa ahụ buru ibu, ma nwee ike ịzọpụta ndụ. Anyị na-atụ anya ịga n'ihu na ọrụ izizi anyị na olile anya na ọgwụ mgbochi a ga-agbakwunye na ngwa agha achọrọ iji lekwasịrị ọrịa kansa a siri ike ma mechaa mee mgbanwe maka ọtụtụ ndị ọrịa. "

Ọgwụ mgbochi ọrịa cancer ovarian na-elekwasị anya na ngalaba extracellular anti-Müllerian hormone receptor 2 (AMHR2-ED), nke a na-egosipụta na ovaries mana ọ na-apụ n'anya ka nwanyị na-erute ma na-aga n'ihu site na nsọpụ. N'ịmara, ihe ka ọtụtụ n'ime nchọpụta ọrịa cancer ovarian na-eme mgbe menopause gasịrị, AMHR2-ED na-egosipụtakwa ọzọ n'ọtụtụ ọrịa cancer ovarian. Site n'inweta ọgwụ mgbochi dịka Anixa's nke na-elekwasị anya AMHR2-ED mgbe ha rutere menopause, ọrịa cancer ovarian, na akụkọ ihe mere eme bụ otu n'ime ọrịa cancer gynecological kachasị ike, nwere ike igbochi ịmalite ịmalite.

Ọrụ preclinical iji kwalite ọgwụ mgbochi na-aga n'ihu site na Mmemme Mgbochi na National Cancer Institute (NCI), nke na-akwado ntinye ọhụụ nke izizi na biomarkers maka mgbochi ọrịa kansa na mgbochi. Data preclinical nke e bipụtara na Nnyocha Mgbochi Ọrịa Cancer na 2017 na-akwado ọganihu na-aga n'ihu na ọmụmụ ụlọ ọgwụ.

Print Friendly, PDF & Email

Banyere chepụtara

nchịkọta akụkọ

Onye nchịkọta akụkọ nke eTurboNew bụ Linda Hohnholz. Ọ dabere na eTN HQ na Honolulu, Hawaii.

Ahapụ a Comment